Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Chiriac, Ute [VerfasserIn]   i
 Richter, Daniel [VerfasserIn]   i
 Frey, Otto R. [VerfasserIn]   i
 Röhr, Anka C. [VerfasserIn]   i
 Helbig, Sophia [VerfasserIn]   i
 Preisenberger, Judit [VerfasserIn]   i
 Hagel, Stefan [VerfasserIn]   i
 Roberts, Jason A. [VerfasserIn]   i
 Weigand, Markus A. [VerfasserIn]   i
 Brinkmann, Alexander [VerfasserIn]   i
Titel:Personalized piperacillin dosing for the critically Ill
Titelzusatz:a retrospective analysis of clinical experience with dosing software and therapeutic drug monitoring to optimize antimicrobial dosing
Verf.angabe:Ute Chiriac, Daniel C. Richter, Otto R. Frey, Anka C. Röhr, Sophia Helbig, Judit Preisenberger, Stefan Hagel, Jason A. Roberts, Markus A. Weigand and Alexander Brinkmann
E-Jahr:2021
Jahr:3 June 2021
Umfang:13 S.
Fussnoten:Gesehen am 18.08.2021
Titel Quelle:Enthalten in: Antibiotics
Ort Quelle:Basel : MDPI, 2012
Jahr Quelle:2021
Band/Heft Quelle:10(2021), 6, Artikel-ID 667, Seite 1-13
ISSN Quelle:2079-6382
Abstract:Optimization of antibiotic dosing is a treatment intervention that is likely to improve outcomes in severe infections. The aim of this retrospective study was to describe the therapeutic exposure of steady state piperacillin concentrations (cPIP) and clinical outcome in critically ill patients with sepsis or septic shock who received continuous infusion of piperacillin with dosing personalized through software-guided empiric dosing and therapeutic drug monitoring (TDM). Therapeutic drug exposure was defined as cPIP of 32-64 mg/L (2-4× the ‘MIC breakpoint’ of Pseudomonas aeruginosa). Of the 1544 patients screened, we included 179 patients (335 serum concentrations), of whom 89% achieved the minimum therapeutic exposure of >32 mg/L and 12% achieved potentially harmful cPIP > 96 mg/L within the first 48 h. Therapeutic exposure was achieved in 40% of the patients. Subsequent TDM-guided dose adjustments significantly enhanced therapeutic exposure to 65%, and significantly reduced cPIP > 96 mg/L to 5%. Mortality in patients with cPIP > 96 mg/L (13/21; 62%) (OR 5.257, 95% CI 1.867-14.802, p = 0.001) or 64-96 mg/L (30/76; 45%) (OR 2.696, 95% CI 1.301-5.586, p = 0.007) was significantly higher compared to patients with therapeutic exposure (17/72; 24%). Given the observed variability in critically ill patients, combining the application of dosing software and consecutive TDM increases therapeutic drug exposure of piperacillin in patients with sepsis and septic shock.
DOI:doi:10.3390/antibiotics10060667
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/antibiotics10060667
 Volltext: https://www.mdpi.com/2079-6382/10/6/667
 DOI: https://doi.org/10.3390/antibiotics10060667
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:continuous infusion
 dosing software
 piperacillin
 PK/PD
 therapeutic drug monitoring
K10plus-PPN:1767270100
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68771667   QR-Code
zum Seitenanfang